Immune Response of Haemodialysis Patients Post Covid-19 Vaccination

NCT ID: NCT04872751

Last Updated: 2021-05-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

425 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-27

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess immune response of end stage renal failure patients after Covid 19 vaccination

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immune Response Post Covid 19 Vaccination

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ESRF patient on hemodialysis who are eligible for the goverment Covid 19 vaccination programme
* 18 years old and above
* consented to join the study

Exclusion Criteria

* patient who refused to be vaccinated
* patient who deemed unsuitable for Covid vaccination
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Penang Hospital, Malaysia

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr.Ong Loke Meng

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

LokeMeng Ong

Role: PRINCIPAL_INVESTIGATOR

Penang Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Penang Hospital

George Town, Pulau Pinang, Malaysia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

XueFang Tan

Role: CONTACT

6042225333 ext. 5576

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ong Loke Meng, FRCS

Role: primary

00 604 2225333 ext. 5767

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NMRR-21-634-59445

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COVID-19 Vaccine Boosters in Patients With CKD
NCT05022329 TERMINATED PHASE2/PHASE3